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EGFR kinaseHuman ether á-go-go gene potassium channels (hEAG1 or Kv10.1) are expressed in brain and various human
cancers and play a role in neuronal excitement and tumor progression. However, the functional regulation of
hEAG channels by signal transduction is not fully understood. The present study was therefore designed to
investigate whether hEAG1 channels are regulated by protein tyrosine kinases (PTKs) in HEK 293 cells stably
expressing hEAG1 gene using whole-cell patch voltage-clamp, immunoprecipitation, Western blot, and mu-
tagenesis approaches. We found that the selective epidermal growth factor receptor (EGFR) kinase inhibitor
AG556 (10 μM), but not the platelet growth factor receptor (PDGFR) kinase inhibitor AG1295 (10 μM) or the
Src-family inhibitor PP2 (10 μM), can inhibit hEAG1 current, and the inhibitory effect can be reversed by the
protein tyrosine phosphatase (PTP) inhibitor orthovanadate. Immunoprecipitation and Western blot analysis
revealed that tyrosine phosphorylation level of hEAG1 channels was reduced by AG556, and the reduction
was signiﬁcantly countered by orthovanadate. The hEAG1 mutants Y90A, Y344A and Y485A, but not Y376A
and Y479A, exhibited reduced response to AG556. Interestingly, the inhibition effect of AG556 was lost in tri-
ple mutant hEAG1 channels at Y90, Y344, and Y485 with alanine. These results demonstrate for the ﬁrst time
that hEAG1 channel activity is regulated by EGFR kinase at the tyrosine residues Tyr90, Try344, and Try485. This
effect is likely involved in regulating neuronal activity and/or tumor growth.
© 2011 Elsevier B.V. All rights reserved.1. Introduction
Human ether á-go-go gene potassium channels (hEAG1 or Kv10.1)
are expressed in the nervous system [1,2] and various human cancers
[3–6] and are believed to play a role in neuronal excitement [1,7]
and tumor progression [3,4,6]. Knockdown of hEAG1 channels by
hEAG1 siRNA suppressed cell proliferation in several human tumor
cell lines [8], while activation of hEAGl channels by arachidonic acid
enhanced cell proliferation in human melanoma cells [9]. Earlier
studies demonstrated that hEAG1 was regulated by Ca2+/calmodulin
[10,11], calmodulin-dependent kinase II [12], and cyclic AMP [1], and
membrane-associated guanylate kinase adaptor proteins [13].
Protein tyrosine kinases (PTKs), including both receptor PTKs
(e.g. EGFR kinase, epidermal growth factor receptor kinase) and
non-receptor PTKs (e.g. Src-family kinases), are important intracellu-
lar signals [14,15]. In addition to the mediation of cellular events such
as cell growth, differentiation, embryonic development, metabolism,
immune system function and oncogenesis [14,15], PTKs regulate
ion channels activity [16,17], including K+ channels [18–21], Na+FMB, The University of Hong
. Tel.: +852 2819 9513; fax:
l rights reserved.channels [22], and Cl− channels [23]. We recently found that
human ether á-go-go related gene (hERG or Kv11.1) potassium chan-
nels were regulated by both EGFR kinase and Src-family kinases
[19]; however, the potential regulation of the super-family hEAG1
channels by PTKs is unknown. The present study was therefore to
determine whether and how hEAG1 channels stably expressed in
HEK 293 cells are regulated by PTKs using whole-cell patch voltage-
clamp, immunoprecipitation, Western blot, and site-directed
mutagenesis approaches. We found that the EGFR kinase inhibitor
AG556, but not the Src-family kinase inhibitor PP2, inhibited hEAG1
current by decreasing tyrosine phosphorylation of the channel.
2. Materials and methods
2.1. Cell culture, mutagenesis, and gene transfection
The plasmid hEAGl/pTracer CMV [8] was generously provided by
Dr. L. Pardo and was transfected into HEK 293 cells (ATCC, Manassas,
VA). The HEK 293 cell line stably expressing hEAG1 channels were
established as previously described [24,25], and selected with
800 μg/ml zeocin (Invitrogen, Hong Kong, China). The cell line was
cultured in Dulbecco's modiﬁed Eagle's medium (DMEM, Invitrogen,
Hong Kong) supplemented with 10% fetal bovine serum, 300 μg/ml
zeocin.
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channels were examined using the software NetPhos 2.0 (www.cbs.
dtu.dk/cgi-bin). The mutant hEAG1 channels were generated using
the QuickChange site-directed mutagenesis kit (Stratagene, La Jolla,
CA, USA) following the manufacturer's instructions, and conﬁrmed
by full DNA sequencing analysis (Gene Centre, University of Hong
Kong). The mutants Y90A, Y344A, Y376A, Y479A, Y485A, Y639A and
Y639F were transiently expressed separately in HEK 293 cells using
10 μl of Lipofectamine 2000 with 4 μg of the plasmid in a 35 mm cul-
ture dish. The cells used for electrophysiology were seeded on a glass
cover slip.
2.2. Solutions and chemicals
Tyrode solution contained (mM)NaCl 140, KCl 5.4,MgCl2 1.0, CaCl2
1.8, 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES)
10.0 and glucose 10 (pH adjusted to 7.3 with NaOH). For whole-cell
current recordings, the pipette solution contained (mM) KCl 20, K-
aspartate 110, MgCl2 1.0, HEPES 10, ethyleneglycoltetraacetic acid
(EGTA) 5, GTP 0.1, Na2-phosphocreatine 5 andMg-ATP 5 (pH adjusted
to 7.2 with KOH).
3-(4-Chlorophenyl) 1-(1,1-dimethylethyl)-1H-pyrazolo[3,4-d]
pyrimidin-4-amine (PP2) was purchased from Tocris (Bristol, UK).
All other reagents were obtained from Sigma-Aldrich (St Louis, MO,
USA). Stock solutions were made with dimethylsulfoxide (DMSO)
for AG556 (100 mM), AG1295 (20 mM) and PP2 (10 mM). The stocks
were divided into aliquots and stored at −20°C. Sodium orthovana-
date stock solution (200 mM) was made with distilled water, and
pH was adjusted to 9.0.
2.3. Electrophysiology
Cells on a coverslip were transferred to a cell chamber (0.5 ml)
mounted on the stage of an inverted microscope (Diaphot, Nikon,
Japan) and superfused at ~2 ml/min with Tyrode solution. Whole-
cell currents were recorded as described previously [24,25]. Borosili-
cate glass electrodes (1.2-mmOD)were pulled with a Brown–Flaming
puller (model P-97, Sutter Instrument Co, Novato, CA) and had tip
resistances of 2–3 MΩ when ﬁlled with the pipette solution. A 3-M
KCl−agar bridgewas used as the reference electrode. The tip potential
was zeroed before the patch pipette contacted with the cell. After a
gigaohm seal was obtained by negative pressure, the cell membrane
was ruptured by applying a gentle suction to establish whole cell
conﬁguration. Series resistance (Rs, 3–6 MΩ) was compensated by
60–80% to minimize voltage errors. The liquid junction potential
(13.5 mV) was not corrected throughout the experiment. Membrane
currents were recorded using an EPC-10 ampliﬁer and Pulse software
(Heka Elektronik, Lambrecht, Germany). Command pulses were
generated by a 12-bit digital-to-analog converter controlled by Pulse
software. Current signals were low-pass ﬁltered at 5 kHz and stored
in the hard disk of an IBM compatible computer. All experiments
were conducted at room temperature (22–23 °C).
2.4. Immunoprecipitation and Western blotting
The immunoprecipitation and Western blotting were performed
following the procedure as described previously [19,20]. HEK 293
cells (~80% conﬂuence) stably expressing hEAG1 channels were
treated respectively with different compounds for 30 min at room
temperature, and centrifuged (400×g for 10 min) at 4 °C. The cell
pellet was then lysed with lysis buffer containing (mM) Tris 25,
NaCl 150, NaF 1.0, EDTA 1.0, orthovanadate 1.0, phenylmethylsulfo-
nyl ﬂuoride 1.0, and 1% Na deoxycholate, 0.1% SDS, 1% Triton X-100,
1 μg/ml leupeptin, and 1 μg/ml aprotinin. Protein quantiﬁcation of
lysates was made using a protein assay reader (Bio-Rad Laborato-
ries, Hercules, CA, USA), and diluted to equal concentrations.Proteins were immunoprecipitated overnight at 4 °C using 2 μg of
anti-KCNH1 (i.e. anti-hEAG1) antibody (NBP1-42816, Novus Biolog-
icals, Littleton, CO, USA) and 100 μl of protein A/G beads (DAM
1460243, Millipore, Billerica, MA, USA). Immunoprecipitated pro-
teins bound to pelleted protein A/G beads were washed thoroughly
in PBS, denatured in Laemmli sample buffer, separated using SDS-
PAGE, and electroblotted onto nitrocellulose membranes. The im-
munoblots were probed with anti-phosphotyrosine antibody
(1:1000, Cell Signaling Technology Inc., Danvers, MA, USA) over-
night at 4 °C in a blocking solution containing 5% BSA in TBS and
Tween 20, and subsequently treated with goat anti-mouse IgG-
HRP antibody (1:5000, Santa Cruz Biotechnology) for 2 h at room
temperature. Blots were developed with enhanced chemilumines-
cence (ECL, Amersham Biosciences, Sweden) and exposed on an X-
ray ﬁlm (Fuji Photo Film GmbH). The blots were then stripped and
reprobed with the anti-hEAG1 antibody to determine total hEAG1
channel proteins. The ﬁlm was scanned, imaged by a Bio-Imaging
System (Syngene, Cambridge, UK), and analyzed via GeneTools soft-
ware (Syngene).
2.5. RNA interference
Short interference RNA (siRNA) molecules targeting human EGFR
(sc-29301) were purchased from Santa Cruz Biotech. This siRNA is a
mixture of three target-speciﬁc 20–25 nucleotide siRNAs designed
to knock down human EGFR gene expression. HEAG1-HEK 293 cells
at 40–50% conﬂuence were transfected with siRNA molecules at a
total of 40 nM using Lipofectamine 2000 reagent (Invitrogen) in
accordance with the manufacturer's protocol. The silencer negative
control #1 siRNA (Ambion, #AM4611; Austin, TX), which contains
no known target in mammalian genomes, was used as negative con-
trol. After 72 h of transfection, the cells were used for immunoprecip-
itation and Western blotting analysis as described above.
2.6. Statistical analysis
Data are expressed as means±S.E.M. Nonlinear curve-ﬁtting was
performed using Pulseﬁt (HEKA) and Sigmaplot (SPSS, Chicago, IL).
Paired and/or unpaired Student's t-test was used as appropriate to
evaluate the statistical signiﬁcance of differences between two
group means, and ANOVA was used for multiple groups. Values of
Pb0.05 were considered to be statistically signiﬁcant.
3. Results
3.1. Effects of PTKs inhibitors on hEAG1 current
The PTKs effects on hEAG1 current were investigated by applying
the highly selective EGFR kinase inhibitor AG556 [26], the selective
platelet growth factor receptor (PDGFR) kinase inhibitor AG1295
[27], and the Src-family kinases inhibitor PP2 [28]. Fig. 1A shows the
time course of hEAG1 current recorded at +50 mV (Fig. 1A) in the
absence and presence of 10 μM AG556. AG556 gradually reduced
the current. The inhibitory effect reached a steady-state level within
5 min upon AG556 exposure, and recovered rapidly on washout.
Voltage-dependent hEAG1 current (Fig. 1B) was also inhibited by
10 μM AG556 (8 min), and the effect recovered on washout. Fig. 1C
illustrates the mean values of current–voltage (I–V) relationships of
hEAG1 current in the absence and presence of 10 μM AG556. The cur-
rent was signiﬁcantly suppressed at potentials from +30 to +60 mV
(n=6, Pb0.01 vs. control).
Voltage-dependent variables (g) of hEAG1 current were calculated
for each cell with I–V relationship curves as shown in Fig. 1C based on
the formulation g=I/(VT−VR), where I is the current at test potential
(VT), and VR is the measured reversal potential (−70 mV). The
normalized current (Fig. 2A) was ﬁtted to a Boltzmann equation as
Fig. 1. Effect of AG556 on hEAG1 current. A. Time-course of hEAG1 current recorded in
a representative cell with a 300-ms voltage step to +50 mV from a holding potential of
−80 mV, then back to −40 mV (inset) in the absence and presence of 10 μM AG556.
Original current traces at corresponding time points are shown in the right of the
panel. B. Voltage-dependent hEAG1 current traces recorded in a typical experiment
with 300-ms voltage steps from −80 mV to between −60 and +60 mV, then back
to −40 mV (inset) under control conditions, in the presence of 10 μM AG556, and
upon washout. C. I–V relationships of hEAG1 current (n=6, **Pb0.01 vs. control).
Fig. 2. AG556 on holding potential-dependent kinetics of hEAG1 current. A. Normalized
variables of hEAG1 current activation in the absence and presence of AG556 were ﬁtted
to the Boltzmann equation as described previously [18]. B. Holding potential-
dependent hEAG1 current was recorded in a representative cell with 1-s conditioning
holding potentials between −100 and −20 mV, then step (300-ms) to +50 mV
(inset), in the absence and presence of 10 μM AG556. C.Mean values of time to 80% ac-
tivation of hEAG1 current at conditioning holding potentials of −100 and −20 mV.
AG556 reversibly reduced the time to 80% activation of the current (n=6, **Pb0.01
vs. control).
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hEAG1 current was negatively shifted from 15.5±1.6 mV in control
to 0.1±3.3 mV with 10 μM AG556 (n=4, Pb0.01). The effect was
reversed by washout (14.7±3.0 mV Pb0.01 vs AG556). The slope
factor was increased from 17.1±0.7 mV in control to 23.5±1.1 mV
with 10 μM AG556 (Pb0.01 vs control), and recovered on washout
(18.0±0.4 mV).
Earlier studies reported that EAG channel current exhibited the
property of holding potential-dependent activation, i.e. slower activa-
tion at hyperpolarization potentials [29,30]. We found that activation
of hAEG1 current rapidly reached a steady-state level during 300-ms
depolarization at holding potential of −50 mV, but not at a holding
potential of −80 mV, in human bone marrow-derived mesenchymal
stem cells [31], supporting the notion that the activation process of
hEAG1 current depends on holding potential. Fig. 2B illustrates the
hEAG1 current traces and voltage protocol (1-s conditioning holding
potentials to between −100 and −20 mV, then step to a 300-ms
test potential of +50 mV) used to evaluate activation time to 80%
current amplitude [30] during control, in the presence of 10 μM
AG556, and after washout (8 min). The time to 80% current activation
decreased as the conditioning holding potential became more
positive, and AG556 reversibly inhibited amplitude and time to 80%
activation of hEAG1 current. The mean value of the time to 80%
was signiﬁcantly reduced with AG556 at all conditioning potentials(n=5, Pb0.01 vs control). AG556-induced modiﬁcation of hEAG1
kinetics recovered almost fully on washout (Fig. 2C).
Fig. 3 illustrates the effects of the selective platelet growth factor
receptor (PDGFR) kinase inhibitor AG1295, and the Src-family
kinases inhibitor PP2 on hEAG1 current in representative cells.
AG1295 (10 μM) or PP2 (10 μM) had no effect on hEAG1 current
with 10 min exposure. The current (+50 mV) was 289±14 pA/pF
in control and 287±11 pA/pF (n=8, P=NS vs control) after 10 μM
AG1295. For PP2 group, the current was 302±14 pA/pF in control
and 298±12 pA/pF (n=7, P=NS vs control) after 10 μM PP2.
These results suggest that the EGFR kinase inhibitor AG556, but not
PDGFR kinase inhibitor AG1295 or the Src-family kinase inhibitor
PP2, inhibits hEAG1 current in HEK cells stably expressing hEAG1
gene.
3.2. Orthovanadate on AG556 effect
To exclude the possibility that the decrease of hEAG1 current by
AG556 was mediated by a direct channel block, the PTP inhibitor
orthovanadate was employed to examine whether the inhibitory
effect of AG556 on hEAG1 current is through EGFR kinase inhibition
(Fig. 4). Orthovanadate at 1 mM had no effect on hEAG1 current
(n=5, data not shown); however, it signiﬁcantly reversed the inhib-
itory effect of voltage-dependent hEAG1 current induced by AG556
(Fig. 4A). Fig. 4B displays the time-course of hEAG1 current recorded
at +50 mV in a typical experiment during control, in the presence of
Fig. 3. AG1295 and PP2 on hEAG1 current. A. Voltage-dependent hEAG1 current traces
recorded in a typical experiment with the voltage protocol as in Fig. 1B in the absence
and presence of 10 μM AG1295. B. Voltage-dependent hEAG1 current traces recorded
in a representative cell in the absence and presence of 10 μM PP2. C. Mean percentage
values of hEAG1 current in the absence (control) and presence of AG1295 or PP2
(n=7–8, P=NS vs. control).
Fig. 4. Effect of orthovanadate on AG556-induced hEAG1 reduction. A. Voltage-
dependent hEAG1 current traces recorded in a typical experiment with the voltage
protocol as in Fig. 1B in control, after the application of 10 μM AG556 or AG556 plus
1 mM orthovanadate. B. Time-course of hEAG1 current recorded in a representative
cell with the voltage protocol shown in the left inset. The inhibition of hEAG1 current
by AG556 was countered by orthovanadate. The original current traces at the corre-
sponding time points are shown in the right. C. Mean percentage values of hEAG1
current (+50 mV) in control, in the presence of 10 μM AG556, and AG556 plus
1 mM orthovanadate (OV). Inhibition of hEAG1 current by AG556 (n=8, **Pb0.01
vs. control) was signiﬁcantly antagonized by orthovanadate (n=8, ##Pb0.01 vs.
AG556 alone). D. Western blot image of EGFR protein in HEK 293 cells with and with-
out hEAG1 gene expression.
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hEAG1 current by AG556 was rapidly countered by orthovanadate.
Fig. 4C illustrates the mean percentage values of hEAG1 current at
+50 mV during control, after the application of AG556, and AG556
plus orthovanadate. The current was reduced by 45.1±4.7% with
10 μM AG556 (n=8, Pb0.01 vs control), and the inhibiting effect of
AG556 was antagonized by 1 mM orthovanadate to 2.9±1.1% of con-
trol (n=8, Pb0.01 vs AG566 alone). These results suggest that inhib-
itory effect of hEAG1 current by AG556 is likely mediated by EFGR
kinase inhibition. Western blot analysis revealed that EGFR expres-
sion was signiﬁcant in HEK 293 cells (Fig. 4D), consistent with previ-
ous report [32].
Fig. 5 shows that the modiﬁcation of activation conductance
(Fig. 5A) and voltage-dependent activation process (Fig. 5B and C)
induced by the EGFR kinase inhibitor AG556 could be signiﬁcantly
countered by the PTP inhibitor orthovanadate.
3.3. Tyrosine phosphorylation level of hEAG1 channels
If the hEAG1 current reduction by AG556 is mediated by EGFR
kinase inhibition, tyrosine phosphorylation level of hEAG1 channel
protein should be reduced by this inhibitor. Fig. 6A and B shows the
immunoprecipitation and Western blot images in hEAG1 HEK 293
cells treated with vehicle (control), 1 mM orthovanadate, 10 μM
AG556, orthovanadate plus AG556, 10 μM PP2, or 100 ng/ml EGF.
Tyrosine phosphorylation level of hEAG1 channel protein was
reduced by AG556, and the reduction was antagonized by orthovana-
date. No signiﬁcant change was observed in cells treated with ortho-
vanadate, EGF, or PP2. Fig. 6D illustrates the mean percentage valuesof pTyr-hEAG1 level relative to hEAG1 channel protein. Tyrosine
phosphorylation level of hEAG1 channel protein was signiﬁcantly
decreased by AG556 (n=5–7, Pb0.01 vs control), but not by PP2.
These results indicate the hEAG1 channel activity is regulated by
EGFR kinase, but not by Src-family kinases. Orthovanadate or EGF
alone had no effect on the tyrosine phosphorylation level or the
hEAG1 current (n=5, data not shown). This suggests that tyrosine
phosphorylation level of hEAG1 channels is saturated under control
conditions. Interestingly, tyrosine phosphorylation level was remark-
ably reduced in hEAG1-HEK cells transfected with 40 nM siRNA
targeting EGFR (Fig. 6C and D), supporting the notion that the satu-
rated tyrosine phosphorylation of hEAG1 channels is mediated by
EGFR kinase.3.4. Tyrosine phosphorylation sites of hEAG1 channels
To determine the molecular regulation sites of EGFR kinase, seven
mutants at different tyrosine sites of hEAG1 channels were generated,
including Y90A, Y344A, Y376A, Y479A, Y485A, Y639A and Y639F. The
mutant Y639A or Y639F showed no functional currents (data
not shown). This may suggest that Tyr639 is likely a critical amino
acid residue in the C-terminus for maintaining functional hEAG1
channels and changes at Tyr639may cause a signiﬁcant conformational
alteration leading to functional loss of hEAG1 channels.
Fig. 5. Antagonism of AG556 effect on holding potential-dependent kinetics of hEAG1
current by orthovanadate. A. Normalized variables of hEAG1 current activation in the
absence and presence of AG556 or AG556 plus orthovanadate (OV) were ﬁtted
(n=5) to the Boltzmann equation as described previously [18]. B. Holding potential-
dependent hEAG1 current was recorded in a typical experiment with the protocol as
shown in Fig. 4A in the absence and presence of 10 μM AG556 or AG556 plus 1 mM
orthovanadate. C.Mean values of time to 80% activation of hEAG1 current at condition-
ing holding potentials between −100 and −20 mV. AG556 reversibly reduced the
time to 80% activation of the current (n=6, **Pb0.01 vs control, #Pb0.01 vs AG556
alone).
Fig. 6. Tyrosine phosphorylation levels of hEAG1 channels. A and B. Images of immuno-
precipitation andWestern blot for tyrosine phosphorylation level of hEAG1 channels in
cells treated vehicle (control), 1 mM orthovanadate (OV), 10 μM AG556, AG556 plus
orthovanadate, 10 μM PP2, or 100 ng/ml EGF. C. Images of immunoprecipitation and
Western blot for tyrosine phosphorylation level of hEAG1 channels in cells transfected
with control siRNA and EGFR siRNA, respectively (40 nM), D. Mean values of the rela-
tive tyrosine phosphorylation level of hEAG1 channel protein in the cells treated with
orthovanadate, AG556, AG556 plus orthovanadate, PP2, or EGF with the concentration
as described in A (n=4–7 experiments, **Pb0.01 vs. control; #Pb0.05 vs AG556
alone), and in the cells transfected with control siRNA or EGFR siRNA (n=3,
##Pb0.01 vs. control siRNA).
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other mutants to the EGFR kinase inhibitor AG556. With 10 μM
AG556, similar inhibitory effect was observed in WT-hEAG1, and
the mutants Y376A and Y479A; however, a reduced inhibition was
observed in the mutants Y90A, Y344A and Y485A. Fig. 7B shows the
current in a representative cell expressing the triple mutant gene
with Y90A, Y344A and Y485A. The cells with triple mutant hEAG
channel lost sensitivity to AG556. Fig. 7C illustrates the mean percent-
age values of AG556 inhibition for different mutant hEAG1 channels.
AG556 at 10 μM reduced hEAG1 current (+50 mV) by 66.5±5.9%
for WT (n=6, Pb0.01 vs. control), 33.7±1.7% for Y90A (n=7,
Pb0.01 vs. WT), 34.0±6.0% for Y344A (n=5, Pb0.01 vs. WT), 61.7±
5.6% for Y376A (n=6, P=NS vs. WT), 67.9±7.8% for Y479A (n=5,
P=NS vs. WT), 31.5±3.8% for Y485A (n=5, Pb0.01 vs. WT), and
2.8±1.2% for triple mutant hEAG1 channels with Y90A, Y344A, and
Y485A (n=5, Pb0.01 vs. WT, Y376A, or Y479A; Pb0.05 vs.Y90A,
Y344A, or Y485A).
Fig. 8A illustrates the 50% concentrations (IC50s) of AG556 for inhi-
biting WT and mutants of hEAG1 channels (at +50 mV). The IC50
was 6.1±1.2 μM (n=6) for WT, 6.7±1.1 μM for Y376A (n=6) and
5.8±1.2 μM for Y479A (n=5) (P=NS vs .WT). However, the IC50
was 16.8±0.9 μM for Y90A (n=7), 17.9±1.4 μM for Y344A (n=5),
and 37.1±0.9 μM for Y485A (n=5, Pb0.01 vs. WT, Y376A or
A479A). The IC50 value for the triple mutant channel of Y90A, Y344A
and Y485A cannot be obtained due to lack of sensitivity to AG556.
These results indicate that three tyrosine residues, Tyr90, Tyr344 and
Tyr485, but not Tyr376 and Tyr479, are involved in tyrosinephosphorylation of hEAG1 channels. These three residues are located
in different sections of hEAG1 channels. Y90 resides in the N-
terminus of the hEAG1 channel and Y485 is located in the C-
terminus while Y344 is in the cytoplasmic section between S4 and
S5 (Fig. 8B).
4. Discussion
The present study demonstrates that the suppression of EGFR
kinase with the selective inhibitor AG556, but not Src-family kinases
with PP2, reduces hEAG1 current and tyrosine phosphorylation level
in HEK 293 cells stably expressing hEAG1 gene. The inhibition is
countered by the PTP inhibitor orthovanadate. Mutagenesis reveals
that EGFR kinase likely regulates hEAG1 channels via phosphorylating
the tyrosine residues Tyr90, Try344 and Try485.
4.1. Previous reports regarding hEAG1 channel regulation
An earlier study reported that intracellular free Ca2+ was a nega-
tive regulator of rat EAG channel [29]. Recent reports have proved
that calmodulin is the Ca2+ sensor for the modulation of hEAG1
channels [10,11]. In contrast to Ca2+-activated potassium channels
[33], hEAG1 channels are inhibited by Ca2+/calmodulin via Ca2+
binding at the N- and C-termini [11]. However, cyclic AMP enhanced
the EAG channel activity [1,2]. The proliferation of cancer cells is
potentially modulated through the functionally expressed hEAG1
channels whose activities are regulated by Ca inﬂux or K ﬂuxes.
Although it is well documented that PTKs participate in regulating
Fig. 7. Effects of AG556 on WT and mutant hEAG1 channels. A. Voltage-dependent current traces recorded with the voltage protocol shown in the inset of Fig. 1B in representative
cells expressing WT, Y90A, Y344A, Y376A, Y479A, and Y485A, respectively, before and after application of 10 μM AG556. B. Voltage-dependent current traces recorded in a repre-
sentative cell expressing the triple mutant gene with Y90A, Y344A and Y485A before and after application of 10 μM AG556. C. Mean percentage values of hEAG1 channel current
(+50 mV) of different mutants (n=5–7, **Pb0.01 vs WT, #Pb0.05 vs. Y90A, Y344A, or Y485A).
Fig. 8. Concentration-dependent effects of AG556 on hEAG1 current. A. Concentration–
response relationships of AG556 for inhibitingWT andmutant hEAG1 channel currents.
Data were ﬁtted to the Hill equation: E=Emax/[1+(IC50/C)b], where E is the inhibition
of hERG1 current in percentage at concentration C, Emax is the maximum inhibition,
IC50 is the concentration for half-maximum inhibition, and b is the Hill coefﬁcient.
B. Schematic model for the regulation of hEAG1 channels by EGFR kinase. Tyrosine
residues of the hEAG1 channels at Tyr90, Tyr344 and Tyr485 (red), but not Tyr376 and
Tyr479 are phosphorylated by EGFR kinase. AG556 inhibited EGFR kinase via reducing
the channel phosphorylation, and the effect may be countered by orthovanadate
through inhibiting the channel dephosphorylation.
287W. Wu et al. / Biochimica et Biophysica Acta 1823 (2012) 282–289ion channel activity [16,17], including several types of K+ channels
[16,34–36] and L-type Ca2+ channels [37,38], as well as volume
sensitive Cl− channels [23,39] in different types of cells, it is unknown
whether there is potential modulation of hEAG1 channels by PTKs.
The present study provides the novel information that hEAG1 chan-
nels are regulated by EGFR kinase, but not by Src-family kinases.4.2. Novel ﬁndings of the present study
The potential regulation of ion channels by PTKs is generally based
on the response to PTK inhibitors (e.g. AG556, PP2, etc.) and whether
the effects induced by the PTK inhibitors can be countered by a PTP
inhibitor [16,19,22,23,37]. We found that the highly selective EGFR
kinase inhibitor AG556 [26] reversibly inhibited the hEAG1 current
amplitude and modiﬁed the holding potential-dependent activation
kinetics. The IC50 (6.1 μM) of AG556 for inhibiting WT hEAG1 chan-
nels is close to those of inhibiting EGFR kinase and cardiac INa
(7.6 μM) [22] or hERG channels (5.2 μM) [19]. However, the PDGFR
kinase inhibitor AG1295 (10 μM) or the Src-family kinase inhibitor
PP2 (10 μM) had no such effect, even at concentrations 20 times
higher than IC50s for inhibiting PDGFR kinase [27] or 2000 times
higher than IC50s for inhibiting Src-family kinases [28]. In addition,
the PTP inhibitor orthovanadate signiﬁcantly countered the reduced
current amplitude and the modiﬁed holding potential-dependent
activation kinetics by AG556. These results suggest that EGFR kinase,
but not PDGRF kinase or Src-family kinases likely regulates hEAG1
channels. This is conﬁrmed by the results with the immunoprecipita-
tion and Western blot analysis: human EAG1 channel phosphoryla-
tion level was reduced by AG556, and the reduced phosphorylation
is signiﬁcantly countered by the PTP inhibitor orthovanadate. In addi-
tion, our experiment with EGFR siRNA showed a remarkable reduc-
tion of tyrosine phosphorylation level of hEAG1 channels, which
further supports the notion that hEAG1 channels are regulated by
EGFR kinase in hEAG1-HEK 293 cells.
Importantly, we found three tyrosine residues are located at Tyr90
in N-terminus, Try344 in cytoplasmic region between transmem-
branes S4 and S5, and Try485 in C-terminus are clearly responsible
for the phosphorylation of the channels. The triple mutant sites Y90,
288 W. Wu et al. / Biochimica et Biophysica Acta 1823 (2012) 282–289Y344, and Y485 lack sensitivity to AG556, suggesting that Y90, Y344,
and Y485 are responsible for tyrosine phosphorylation of hEAG1 by
EGFR kinase.
4.3. Comparison with other ion channel regulation by PTKs
Basal tyrosine phosphorylation level of INa in guinea pig ventricu-
lar myocytes [22] and Kir2.3 channels expressed in HEK 293 cells [20]
can be increased by the PTK activator EGF or the PTP inhibitor ortho-
vanadate which signiﬁcantly augments the current amplitude. How-
ever, saturation of basal tyrosine phosphorylation is observed in
Kir2.1 channels [21], hERG channels [19], KCNQ1/KCNE1 channels
[18,40], cardiac native K+ currents [34] and ICa.L [37], in which the
PTP inhibitor and/or EGF was unable to enhance the channel activity.
These channels showed inhibitory response to PTK inhibitors, and the
inhibition effect was signiﬁcantly reversed by the PTP inhibitor ortho-
vanadate [18,19,21,34,37]. In hERG channels, EGF or orthovanadate
did not show any effect even with 36-h FBS-free (starvation) culture
[19]. The hEAG1 channels, like hERG channels, showed no response
to EGF or orthovanadate, even after a 36-h starvation, and was sup-
pressed by the EGFR kinase inhibitor AG556, indicating a saturated
level of basal tyrosine phosphorylation. Although both hEAG1 chan-
nels and hERG channels belong to the same superfamily of K+ chan-
nels, the signal regulation may not be identical. A previous
observation showed that hERG channel current, as ICl.vol [23,41], was
regulated by both Src-family kinases and EGFR kinase [19]. The pre-
sent study demonstrated that hEAG1 channels, like cardiac INa [22]
and IKs [18], were regulated only by EGFR kinase.
4.4. Signiﬁcance and limitation of the present study
Protein and mRNA of hEAG1 channels are expressed in many can-
cer cells, but not their corresponding normal tissues [3–6]. It has been
reported that hEAG1 channels play a role in regulating proliferation of
cancer cells. Silencing hEAG1 by RNA interference or hEAG1 channel
inhibition by monoclonal antibody has been found to remarkably
suppress cell proliferation and tumor progression [8,42]. The modula-
tion of hEAG1 channels by EGFR kinase could therefore affect cell pro-
liferation and tumor progression by changing membrane potential
and intracellular Ca2+ levels. The inhibition of hEAG1 is at least par-
tially responsible for the anticancer effect of speciﬁc EGFR kinase in-
hibitors [43–45]. In addition to the expression of hEAG1 channels in
cancer cells, central neuronal cells highly express this channel [1,7].
Although the information regarding hEAG1 channel function under
biological conditions is limited in neurons, hEAG1 channels may
play a role in modulating neuronal activity [1,7]. Therefore, the regu-
lation of hEAG1 channels by EGFR kinase could affect neuronal
excitability.
One limitation of the present study was that we were unable to
provide the data of phosphorylation level in mutant hEAG1 channels,
because we had the difﬁculty in establishing the stable cell lines for
this purpose, although it is ideal to demonstrate the reduced tyrosine
phosphorylation level in the mutant channels.
Collectively, our study demonstrates for the ﬁrst time that hEAG1
channels are regulated by EGFR kinase. Three tyrosine residues of
the channels at different cytoplasmic regions of the hEAG1 channel
(Tyr90, Try344 and Try485) are involved in phosphorylation with
EGFR kinase, which may be involved in regulating tumor growth/
migration and/or neuronal excitability.
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